Lisinopril/Carvedilol

赖诺普利/卡维地洛

Report date: 2022/07/04 19:38:02

Base Information

Drug NameLisinopril/Carvedilol
Drug Alias NameCoreg CR + ACEi赖诺普利/卡维地洛Lisinopril/carvedilolCOREG CR and lisinopril (FDC)Zestril/COREG CR +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta adrenergic receptors antagonistsAlpha-1a adrenergic receptor antagonistsVoltage-gated calcium channel blockers
TargetsBeta adrenergic receptorsAlpha-1a adrenergic receptorVoltage-gated calcium channel
Therapy Area/IndicationsHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes LisinoprilCarvedilol
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsHypertension

Other Information

ATC CodeN/A
Related LinksN/A